A

fter Mylan shareholders last week rebuked the drug maker by voting against executive compensation, three large pension funds are now calling for Mylan to remove its non-executive chairman and a director in hopes of restoring confidence in the beleaguered board.

In explaining their reasoning, the funds pointed to an “astounding” 83.5 percent of shareholders who did not support executive pay, including a controversial, $97 million package given to non-executive chairman Robert Coury. The funds also noted that a majority of shareholders – 56 percent – voted against re-electing Wendy Cameron, the director who heads the Mylan compensation committee (the numbers are right here).

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.